Annexon stock is trading -85.71% below its average target price of $15.4 after dropping -57.4% during today's afternoon session. Analysts are giving the small-cap Pharmaceutical company an average rating of buy and target prices ranging from $8.0 to $24.0 per share.
The stock has an average amount of shares sold short at 5.2%, and a short ratio of 6.19. At 2.2%, the company's rate of insider ownership does not indicate that management is deeply invested in the company. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.7% of Annexon's shares being owned by this investor type.
Institutions Invested in Annexon
|2023-03-31||Alerce Investment Management, L.P.||13%||7,056,024||$15,523,253|
|2023-03-31||Bain Capital Life Sciences Investors, LLC||9%||4,886,616||$10,750,555|
|2023-03-31||Adage Capital Partners GP L.L.C.||7%||3,549,975||$7,809,945|
|2023-03-31||Redmile Group, LLC||7%||3,503,190||$7,707,018|
|2023-03-31||VR Adviser, LLC||6%||3,220,050||$7,084,110|
|2023-03-31||Federated Hermes, Inc.||6%||3,057,800||$6,727,160|
|2023-03-31||Citadel Advisors Llc||5%||2,413,117||$5,308,857|
|2023-03-31||Eventide Asset Management LLC||4%||1,867,250||$4,107,950|
|2023-03-31||Vanguard Group, Inc. (The)||3%||1,569,971||$3,453,936|
|2023-03-31||GMT Capital Corp||3%||1,408,697||$3,099,133|
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Annexon.